Journal of Surgery Concepts & Practice >

2022 , Vol. 27 >Issue 06: 500 - 505

DOI: https://doi.org/10.16139/j.1007-9610.2022.06.04

Experts forum

Retroperitoneal tumor: pathological diagnosis and differential diagnosis

Expand

Received date: 2022-09-26

  Online published: 2023-01-30

Fold

Cite this article

WANG Jian . Retroperitoneal tumor: pathological diagnosis and differential diagnosis[J]. Journal of Surgery Concepts & Practice, 2022 , 27(06) : 500 -505 . DOI: 10.16139/j.1007-9610.2022.06.04

References

[1] Messiou C, Moskovic E, Vanel D, et al. Primary retroperitoneal soft tissue sarcoma: imaging appearances, pitfalls and diagnostic algorithm[J]. Eur J Surg Oncol, 2017, 43(7):1191-1198.
[2] Makise N, Yoshida A, Komiyama M, et al. Dedifferentia-ted liposarcoma with epithelioid/epithelial features[J]. Am J Surg Pathol, 2017, 41(11):1523-1531.
[3] Agaimy A, Michal M, Hadravsky L, et al. Dedifferentia-ted liposarcoma composed predominantly of rhabdoid/epithelioid cells: a frequently misdiagnosed highly aggressive variant[J]. Hum Pathol, 2018, 77:20-27.
[4] Saada-Bouzid E, Burel-Vandenbos F, Ranchère-Vince D, et al. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas[J]. Mod Pathol, 2015, 28(11):1404-1414.
[5] Schaefer IM, Lundberg MZ, Demicco EG, et al. Relationships between highly recurrent tumor suppressor alte-rations in 489 leiomyosarcomas[J]. Cancer, 2021, 127(15):2666-2673.
[6] Pérot G, Derré J, Coindre JM, et al. Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas[J]. Cancer Res, 2009, 69(6):2269-2278.
[7] Colombo C, Miceli R, Lazar AJ, et al. CTNNB1 45F mutation is a molecular prognosticator of increased posto-perative primary desmoid tumor recurrence: an independent, multicenter validation study[J]. Cancer, 2013, 119(20):3696-3702.
[8] Demicco EG, Wagner MJ, Maki RG, et al. Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model[J]. Mod Pathol, 2017, 30(10):1433-1442.
[9] Tanaka T, Masumori N. Current approach to diagnosis and management of retroperitoneal fibrosis[J]. Int J Urol, 2020, 27(5):387-394.
[10] 徐静, 张勇, 童汉兴, 等. 静脉内平滑肌瘤病的临床特征与外科治疗策略[J]. 中国临床医学, 2019, 26(3):369-373.
[11] Fishbein L, Leshchiner I, Walter V, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma[J]. Cancer Cell, 2017, 31(2):181-193.
[12] Muth A, Crona J, Gimm O, et al. Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma[J]. J Intern Med, 2019, 285(2):187-204.
[13] Burgues O, Navarro S, Noguera R, et al. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma(Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry[J]. Virchows Arch, 2006, 449(4):410-420.
[14] Hoshino Y, Yamada I, Shimano SI. Malignant lymphoma mimicking retroperitoneal fibrosis[J]. Intern Med, 2021, 60(20):3345-3346.
Options
Outlines

/

〈 〉